NCT02581865View on ClinicalTrials.gov

Safety and Efficacy Study of NBI-98854 in Adults With Tourette Syndrome

PHASE2CompletedINTERVENTIONAL
Enrollment

124

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2016

Conditions
Tourette Syndrome
Interventions
DRUG

NBI-98854

DRUG

Placebo

Trial Locations (30)

Unknown

Long Beach

National City

San Bernardino

San Diego

Upland

Gainesville

Hialeah

St. Petersburg

Tampa

Atlanta

Chicago

Boston

Natick

St Louis

Nashua

Summit

Albany

Manhasset

New York

Staten Island

Cincinnati

Oklahoma City

Norristown

Nashville

Dallas

Irving

Orem

Salt Lake City

Kirkland

Spokane

Sponsors
All Listed Sponsors
lead

Neurocrine Biosciences

INDUSTRY